Literature DB >> 33753891

Comparison of IVIG resistance predictive models in Kawasaki disease.

Ummusen Kaya Akca1, Elif Arslanoglu Aydin2, Hayrettin Hakan Aykan3, Oguzhan Serin2, Erdal Sag1, Selcan Demir1, Erdal Atalay1, Muserref Kasap1, Ezgi Deniz Batu1, Tevfik Karagoz3, Yelda Bilginer1, Seza Ozen4.   

Abstract

BACKGROUND: We aimed to compare the ten different scores (by Kobayashi, Egami, Harada, Formosa, Sano, Piram et al., Wu et al., Yang et al., Tan et al., and Kanai et al.) to assess their performance in predicting IVIG resistance in Turkish children.
METHODS: Complete and incomplete KD patients diagnosed with KD at Hacettepe University between June 2007 and September 2019 were evaluated retrospectively.
RESULTS: A total of 129 patients, 79 boys (61.2%), with a median age 36 (IQR 19.5-57.0) months were evaluated. Sixteen patients (12.4%) had IVIG resistance. Sensitivity was low for all the ten scores. Tan, Sano, and Egami predictive models had the highest specificity (97.3, 89.4, 86.7%, respectively). Almost all scoring systems distinguished the group of patients with low risk for IVIG resistance but could not differentiate IVIG-resistant patients. Multivariate analysis for the laboratory features showed that platelet count <300 × 109/L and GGT serum levels were independent risk factors for IVIG resistance (OR: 3.896; 95% CI: 1.054-14.404; p = 0.042 and OR: 1.008; 95% CI: 1.001-1.015; p = 0.050).
CONCLUSIONS: The current scoring systems had a low sensitivity for predicting the risk for IVIG resistance in Turkish children. On the other hand, increased serum GGT levels and low platelet count were risk factors for predicting IVIG resistance. IMPACT: Intravenous immunoglobulin (IVIG) resistance may be observed in 10-20% of patients diagnosed with Kawasaki disease. Coronary artery involvement is more frequent in IVIG-resistant patients. It is important to predict the patients who might develop IVIG resistance to improve prognosis. The performance of the IVIG resistance predictive models in Kawasaki disease in our population is limited due to the low sensitivity.
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33753891     DOI: 10.1038/s41390-021-01459-w

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  Childhood vasculitides in Turkey: a nationwide survey.

Authors:  Seza Ozen; Aysin Bakkaloglu; Ruhan Dusunsel; Oguz Soylemezoglu; Fatih Ozaltin; Hakan Poyrazoglu; Ozgur Kasapcopur; Ozan Ozkaya; Fatos Yalcinkaya; Ayse Balat; Nurdan Kural; Osman Donmez; Harika Alpay; Ali Anarat; Sevgi Mir; Ayfer Gur-Guven; Ferah Sonmez; Faysal Gok
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

2.  Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.

Authors:  Nattika Chantasiriwan; Suchaya Silvilairat; Krit Makonkawkeyoon; Yupada Pongprot; Rekwan Sittiwangkul
Journal:  Paediatr Int Child Health       Date:  2018-05-17       Impact factor: 1.990

  2 in total
  3 in total

Review 1.  Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives.

Authors:  Piotr Buda; Joanna Friedman-Gruszczyńska; Janusz Książyk
Journal:  Front Med (Lausanne)       Date:  2021-11-30

2.  Development of a score for early identification of children with Kawasaki disease requiring second-line treatment in multi-ethnic populations in Europe: A multicentre retrospective cohort study.

Authors:  Naim Ouldali; Rosa Maria Dellepiane; Sofia Torreggiani; Lucia Mauri; Gladys Beaujour; Constance Beyler; Martina Cucchetti; Cécile Dumaine; Adriano La Vecchia; Isabelle Melki; Rita Stracquadaino; Caroline Vinit; Rolando Cimaz; Ulrich Meinzer
Journal:  Lancet Reg Health Eur       Date:  2022-08-06

3.  Value of blood inflammatory markers for predicting intravenous immunoglobulin resistance in Kawasaki disease: A systematic review and meta-analysis.

Authors:  Chang Liu; Jiacheng Wu
Journal:  Front Pediatr       Date:  2022-08-23       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.